Episode 165: Paper of the Month – ENZAMET quality of life data

Martin Stockler describes this paper, which shows mixed effects of enza on QOL in prostate cancer.

Related Episodes

Episode 180: Enzalutamide vs Active Surveillance in Early Prostate Cancer
Episode 179: PSMA PET for Lutetium-177 in Prostate Cancer
Episode 169: The Uromigos Paper of the Month – Novel neoadjuvant approaches in UC
Episode 166: Prostate Cancer Debate: Doublet vs Triplet First Line Therapy
Paper of the month: what can we learn from R3 ipilimumab/nivolumab in gastric cancer
Episode 160: APCCC – PSMA PET as a Diagnostic
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in mCRPC
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide and chemo vs chemo alone in hormone sensitive advanced prostate cancer
Episode 153: ASCO GU 2022 Overview of PARP inhibitors in prostate cancer